M. Tomas

Involvement of Pf-like phages in resistance to phage infection in clinical isolates of P. aeruginosa from cystic fibrosis patients

The paper identifies 12 new Pf-like phages in P. aeruginosa clinical isolates and links their presence to resistance against phage infection through novel anti-phage defence systems.

Control of the phage defence mechanisms by Quorum sensing (QS) in clinical isolates of Klebsiella pneumoniae

This study investigates how cinnamaldehyde inhibits quorum sensing in K. pneumoniae to reduce phage resistance by proteomic analysis and infection assays.

Phages Produce Persisters

This study shows bacteria can survive phage infection through mutation or by forming persisters, which survive without mutation and retain wild-type phage sensitivity.

Molecular Studies of Phages-Klebsiella pneumoniae in a Mucoid Environment: Innovative use of mucolytic agents prior to the administration of lytic phages

This study shows that mucin promotes phage resistance in K. pneumoniae, but mucolytic agents like NAC reduce this resistance, suggesting their potential use in phage therapy.

In vitro and in vivo combination of lytic phages and octapeptin OPX10053 against B-lactamase-producing clinical isolates of Klebsiella pneumoniae

This study evaluates the in vitro and in vivo synergy between lytic phages and octapeptin OPX10053 against K. pneumoniae clinical isolates, showing synergistic activity but toxicity concerns with OPX10053.

Molecular analysis of the interactions between phages and the bacterial host Klebsiella pneumoniae

The paper analyzes molecular defense mechanisms in phages and Klebsiella pneumoniae through proteomic and genomic studies, revealing interactions such as CRISPR-Cas systems and toxin-antitoxin systems.

Application of RT-LAMP-CRISPR-Cas13a technology to the detection of OXA-48 producing Klebsiella pneumoniae

The paper develops an RT-LAMP-CRISPR-Cas13a assay for detecting OXA-48-producing Klebsiella pneumoniae in clinical samples with 100% specificity and sensitivity.

In vitro and in vivo efficacy of the combination of colistin and endolysins against clinical strains of Multi-Drug Resistant (MDR) pathogens

This study evaluates the in vitro and in vivo efficacy of combining colistin with endolysins ElyA1 and ElyA2 against MDR pathogens, finding that ElyA1 enhances colistin's antimicrobial activity and reduces its MIC.